overactive bladder

FDA fast tracks DNA therapy for MS-related bladder issue

The U.S. Food and Drug Administration (FDA) granted fast track designation to EG110A, EG 427‘s DNA-based therapy to treat neurogenic detrusor overactivity (NDO) — a bladder disorder that can arise from spinal cord injury or neurodegenerative conditions such as multiple sclerosis (MS). The FDA gives fast track status to experimental…

Enrollment full in trial of Scone device for overactive bladder

A clinical trial testing SpineX‘s Scone neuromodulation device for treating a neurogenic, or overactive, bladder, a common symptom of multiple sclerosis (MS), has finished enrolling patients. Called CONTINENCE (NCT05301335), the study enrolled adults with overactive bladder due to MS, stroke, or spinal cord injury at…

Knowing Me, Knowing MS

The problem with writing a weekly column is I always need to come up with new ideas. Luckily, or rather, unluckily, MS always throws me a U.S. sports-shaped analogy — one of those trickily disguised curveballs. I wasn’t even going to attempt to write this week. Not because of…